M. Gandhi

发表

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).

M. Kris, V. Rusch, Bruce E. Johnson, 2018 .

K. Syrigos, D. Gandara, R. Dziadziuszko, 2017 .

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.

Keunchil Park, F. de Marinis, J. von Pawel, 2019, Lung cancer.

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

Keunchil Park, D. Gandara, J. von Pawel, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)

M. Kris, V. Rusch, I. Wistuba, 2018, Journal of Thoracic Oncology.

81OSafety and efficacy analyses of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients with or without baseline brain metastases

J. Patel, R. Lukas, M. Gandhi, 2017 .

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Toyoaki Hida, Keunchil Park, D. Gandara, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oral Abstract: MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

A. Alencar, I. Flinn, P. Zinzani, 2022, Clinical Lymphoma Myeloma and Leukemia.

Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK

D. Gandara, R. Dziadziuszko, J. Mazières, 2018, Pneumologie.

Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.

Keunchil Park, D. Gandara, J. von Pawel, 2019, European journal of cancer.

Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.

E. Vokes, D. Kozono, T. Stinchcombe, 2018 .

OA 17.07 Long-Term Survival in Atezolizumab-Treated Patients with 2L+ NSCLC from Ph III Randomized OAK Study

D. Gandara, M. Satouchi, L. Fehrenbacher, 2017 .

Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.

Keunchil Park, D. Gandara, L. Fehrenbacher, 2017 .

Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.

H. Borghaei, R. Ionescu-Ittu, I. Pivneva, 2018, Lung cancer.

MA 10.03 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR)

J. Mazières, J. Vansteenkiste, L. Fehrenbacher, 2017 .

P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab

V. Velcheti, J. Mazières, J. Goldschmidt, 2018, Journal of Thoracic Oncology.